Neumora Therapeutics (NMRA) Common Equity (2022 - 2026)
Neumora Therapeutics' Common Equity was $44.52 million in Q2 2026, down 75.7% from $182.88 million a year earlier and down 37.0% from the prior quarter.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Common Equity (2022 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Neumora Therapeutics came in at $103.87 million, down 63.8% from FY2024.
- In earlier years, Common Equity was $287.06 million in FY2024 (-38.8%), $469.08 million in FY2023 and -$446.85 million in FY2022.
- The Q2 2026 figure marks the lowest quarterly Common Equity since Q2 2023.
- Compared with a year earlier, Common Equity has declined for eight straight quarters, with an average decline of 55.2% over the last eight quarters.
- The year-over-year decline in Common Equity has ranged between 37.4% (Q3 2024) and 75.7% (Q2 2026) over the last five years.
- Per Business Quant data, NMRA's Common Equity in the three quarters before Q2 2026 was $70.68 million (Q1 2026), $103.87 million (Q4 2025) and $132.16 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Neumora Therapeutics | 129.65 Mn | 129.65 Mn | - | 44.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.52 Mn |
| Mar 31, 2026 | 70.68 Mn |
| Dec 31, 2025 | 103.87 Mn |
| Sep 30, 2025 | 132.16 Mn |
| Jun 30, 2025 | 182.88 Mn |
| Mar 31, 2025 | 228.36 Mn |
| Dec 31, 2024 | 287.06 Mn |
| Sep 30, 2024 | 320.74 Mn |
| Jun 30, 2024 | 381.26 Mn |
| Mar 31, 2024 | 424.54 Mn |
| Dec 31, 2023 | 469.08 Mn |
| Sep 30, 2023 | 512.69 Mn |
| Jun 30, 2023 | -513.54 Mn |
| Mar 31, 2023 | -477.92 Mn |
| Dec 31, 2022 | -446.85 Mn |
| Sep 30, 2022 | -422.00 Mn |
API Access
Neumora Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=NMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "NMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=NMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();